HC Wainwright reiterated their buy rating on shares of Belite Bio (NASDAQ:BLTE – Free Report) in a research note released on Thursday morning, Benzinga reports. The firm currently has a $60.00 price target on the stock.
Other analysts have also issued reports about the stock. Benchmark reiterated a buy rating and set a $57.00 target price on shares of Belite Bio in a research report on Tuesday, August 13th. Cantor Fitzgerald reaffirmed an overweight rating on shares of Belite Bio in a report on Thursday, June 20th.
View Our Latest Stock Report on BLTE
Belite Bio Stock Performance
Belite Bio (NASDAQ:BLTE – Get Free Report) last announced its quarterly earnings data on Friday, August 9th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.03). As a group, equities research analysts forecast that Belite Bio will post -1.19 EPS for the current fiscal year.
Hedge Funds Weigh In On Belite Bio
A hedge fund recently bought a new stake in Belite Bio stock. Jump Financial LLC acquired a new position in shares of Belite Bio, Inc (NASDAQ:BLTE – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,200 shares of the company’s stock, valued at approximately $238,000. 0.53% of the stock is currently owned by hedge funds and other institutional investors.
Belite Bio Company Profile
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.
See Also
- Five stocks we like better than Belite Bio
- How Investors Can Find the Best Cheap Dividend Stocks
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
- Differences Between Momentum Investing and Long Term Investing
- Kroger Stock is a Win-Win for Buy-and-Hold Investors
- Where Do I Find 52-Week Highs and Lows?
- MarketBeat Week in Review – 9/9 – 9/13
Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.